You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Carcinoma, Transitional Cell

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma Trial (BGB-A445, Tislelizumab)

Not yet recruiting
  • Urothelial Carcinoma
  • +2 more
  • (no location specified)
Dec 15, 2022

Carcinoma, Transitional Cell Trial in San Francisco (Atezolizumab)

Active, not recruiting
  • Carcinoma, Transitional Cell
  • San Francisco, California
    University of California, San Francisco
May 24, 2022

Adjuvant Radiotherapy and Combined Adjuvant Treatment Strategy

Recruiting
  • Urothelial Carcinoma
  • Radiotherapy
  • +2 more
  • Beijing, China
  • +2 more
Nov 2, 2023

Metastatic Urothelial Carcinoma Trial in Québec (Bicalutamide 150 mg, Placebo)

Not yet recruiting
  • Metastatic Urothelial Carcinoma
  • Bicalutamide 150 mg
  • Placebo
  • Québec, Canada
    CHU de Québec - Université Laval
Sep 6, 2023

Bladder Transitional Cell Carcinoma, Bladder Cancer, Fibroblast Growth Factor Receptor Trial (Infigratinib)

Withdrawn
  • Bladder Transitional Cell Carcinoma
  • +2 more
  • (no location specified)
Aug 8, 2022

Bladder Cancer, Metastatic Transitional Cell Carcinoma Trial in New York (Everolimus)

Completed
  • Bladder Cancer
  • Metastatic Transitional Cell Carcinoma
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 16, 2021

Urothelial Carcinoma Trial in Beijing (18F-FDG)

Recruiting
  • Urothelial Carcinoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jul 18, 2022

Carcinoma, Upper Tract Urothelial Carcinoma, UTUC Trial in Nanjing (RC48-ADC and JS001)

Recruiting
  • Carcinoma
  • +2 more
  • RC48-ADC and JS001
  • Nanjing, Jiangsu, China
    Jinling Hospital, Affiliated Hospital of Medical School, Nanjing
Jun 15, 2023

Urothelial Carcinoma Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 27, 2023

Metastatic Malignancy Trial in Houston (Atezolizumab, Tiragolumab)

Not yet recruiting
  • Metastatic Malignancy
  • Houston, Texas
    M D Anderson Cancer Center
Dec 19, 2022

Carcinoma, Transitional Cell, HER-2 Gene Amplification Trial in Beijing (Trastuzumab)

Recruiting
  • Carcinoma, Transitional Cell
  • HER-2 Gene Amplification
  • Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Mar 31, 2022

Upper Urinary Tract Urothelial Carcinoma, Bladder Cancer Trial in Vienna (Intravesical Solution)

Not yet recruiting
  • Upper Urinary Tract Urothelial Carcinoma
  • Bladder Cancer
  • Intravesical Solution
  • Vienna, Austria
  • +1 more
Mar 31, 2023

Combined Postoperative Radiotherapy With Kidney Sparing Surgery

Recruiting
  • Locally Advanced
  • Urothelial Carcinoma Ureter
  • Radical surgery
  • Kidney sparing surgery+Postoperative radiotheray
  • Beijing, China
  • +1 more
Nov 2, 2023

Bladder Cancer Trial in Lausanne (Flexible cystoscopy, Urinary catheter)

Active, not recruiting
  • Bladder Cancer
  • Flexible cystoscopy
  • Urinary catheter
  • Lausanne, VD, Switzerland
    Centre Hospitalier Universitaire Vaudois, CHUV
Dec 1, 2022

Metastatic Urothelial Carcinoma Trial in Tampa, Boston (Ipilimumab, Nivolumab, Sacituzumab govitecan)

Recruiting
  • Metastatic Urothelial Carcinoma
  • Tampa, Florida
    Moffitt Cancer Center
Jan 24, 2023

CXCL5 asValuable Prognostic Marker in Urinary Bladder Urothelial

Recruiting
  • Urinary Bladder Urothelial Carcinoma
    • Sohag, Egypt
      Faculty of Medicine, Sohag University
    Jul 26, 2022

    Urothelial Carcinoma Trial in New York (Naptumomab Estafenatox, Pembrolizumab, Obinutuzumab)

    Not yet recruiting
    • Urothelial Carcinoma
    • Naptumomab Estafenatox
    • +2 more
    • New York, New York
      Weill Cornell Medicine/NewYork-Presbyterian Hospital
    May 30, 2023

    High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma, Perfusion; Complications, Intraoperative Complications Trial

    Recruiting
    • High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma
    • +2 more
    • hyperthermic intravesical perfusion
    • Zhengzhou, Henan, China
      BR-PRG
    Sep 15, 2022

    Metastatic Cancer, Urothelial Carcinoma Trial (avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin)

    Not yet recruiting
    • Metastatic Cancer
    • Urothelial Carcinoma
    • avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin
    • (no location specified)
    Dec 19, 2022

    Advanced Urothelial Carcinoma Trial in Beijing (9MW2821, Toripalimab)

    Not yet recruiting
    • Advanced Urothelial Carcinoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Oct 9, 2023

    Bladder Urothelial Carcinoma Trial in Nanjing (primary focal resection plus lymph node dissection, Tislelizumab, Gemcitabine

    Recruiting
    • Bladder Urothelial Carcinoma
    • primary focal resection plus lymph node dissection
    • +2 more
    • Nanjing, Jiangsu, China
      The first affiliated hospital of Nanjing Medical University
    Dec 7, 2022

    Urothelial Carcinoma Trial (disitamab vedotin, pembrolizumab, gemcitabine)

    Not yet recruiting
    • Urothelial Carcinoma
    • disitamab vedotin
    • +4 more
    • (no location specified)
    Jun 9, 2023

    Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)

    Not yet recruiting
    • Locally Advanced Urothelial Carcinoma
    • +3 more
    • (no location specified)
    Sep 15, 2022

    Neoadjuvant Immunotherapy Trial in Tianjin (tislelizumab+disitamab-vedotin)

    Recruiting
    • Neoadjuvant Immunotherapy
    • Tianjin, China
      The Second Hospital of Tianjin Medical University
    Apr 20, 2023

    Advanced Urothelial Carcinoma Trial in Bern (Magrolimab, Cisplatin, Gemcitabine)

    Not yet recruiting
    • Advanced Urothelial Carcinoma
    • Bern, Switzerland
      University Hospital Insel
    Feb 20, 2023